Your browser doesn't support javascript.
loading
Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion.
Sun, Xiujie; Wu, Bogang; Chiang, Huai-Chin; Deng, Hui; Zhang, Xiaowen; Xiong, Wei; Liu, Junquan; Rozeboom, Aaron M; Harris, Brent T; Blommaert, Eline; Gomez, Antonio; Garcia, Roderic Espin; Zhou, Yufan; Mitra, Payal; Prevost, Madeleine; Zhang, Deyi; Banik, Debarati; Isaacs, Claudine; Berry, Deborah; Lai, Catherine; Chaldekas, Krysta; Latham, Patricia S; Brantner, Christine A; Popratiloff, Anastas; Jin, Victor X; Zhang, Ningyan; Hu, Yanfen; Pujana, Miguel Angel; Curiel, Tyler J; An, Zhiqiang; Li, Rong.
Affiliation
  • Sun X; Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA.
  • Wu B; Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA.
  • Chiang HC; Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA.
  • Deng H; Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA.
  • Zhang X; Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA.
  • Xiong W; Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA.
  • Liu J; Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA.
  • Rozeboom AM; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
  • Harris BT; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
  • Blommaert E; ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
  • Gomez A; Rheumatology Department and Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain.
  • Garcia RE; ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
  • Zhou Y; Department of Molecular Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.
  • Mitra P; Department of Anatomy and Cell Biology, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA.
  • Prevost M; Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA.
  • Zhang D; Department of Medicine, The Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX, USA.
  • Banik D; Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA.
  • Isaacs C; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
  • Berry D; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
  • Lai C; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
  • Chaldekas K; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
  • Latham PS; Department of Pathology, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA.
  • Brantner CA; GW Nanofabrication and Imaging Center, The George Washington University, Washington, DC, USA.
  • Popratiloff A; GW Nanofabrication and Imaging Center, The George Washington University, Washington, DC, USA.
  • Jin VX; Department of Molecular Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.
  • Zhang N; Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA.
  • Hu Y; Department of Anatomy and Cell Biology, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA.
  • Pujana MA; ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain. mapujana@iconcologia.net.
  • Curiel TJ; Department of Medicine, The Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX, USA. curielt@uthscsa.edu.
  • An Z; Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA. Zhiqiang.An@uth.tmc.edu.
  • Li R; Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA. rli69@gwu.edu.
Nature ; 599(7886): 673-678, 2021 11.
Article de En | MEDLINE | ID: mdl-34732895
Immune exclusion predicts poor patient outcomes in multiple malignancies, including triple-negative breast cancer (TNBC)1. The extracellular matrix (ECM) contributes to immune exclusion2. However, strategies to reduce ECM abundance are largely ineffective or generate undesired outcomes3,4. Here we show that discoidin domain receptor 1 (DDR1), a collagen receptor with tyrosine kinase activity5, instigates immune exclusion by promoting collagen fibre alignment. Ablation of Ddr1 in tumours promotes the intratumoral penetration of T cells and obliterates tumour growth in mouse models of TNBC. Supporting this finding, in human TNBC the expression of DDR1 negatively correlates with the intratumoral abundance of anti-tumour T cells. The DDR1 extracellular domain (DDR1-ECD), but not its intracellular kinase domain, is required for immune exclusion. Membrane-untethered DDR1-ECD is sufficient to rescue the growth of Ddr1-knockout tumours in immunocompetent hosts. Mechanistically, the binding of DDR1-ECD to collagen enforces aligned collagen fibres and obstructs immune infiltration. ECD-neutralizing antibodies disrupt collagen fibre alignment, mitigate immune exclusion and inhibit tumour growth in immunocompetent hosts. Together, our findings identify a mechanism for immune exclusion and suggest an immunotherapeutic target for increasing immune accessibility through reconfiguration of the tumour ECM.
Sujet(s)

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Collagène / Échappement de la tumeur à la surveillance immunitaire / Matrice extracellulaire / Tumeurs du sein triple-négatives / Récepteur-1 à domaine discoïdine Type d'étude: Prognostic_studies Limites: Animals / Female / Humans Langue: En Journal: Nature Année: 2021 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Royaume-Uni

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Collagène / Échappement de la tumeur à la surveillance immunitaire / Matrice extracellulaire / Tumeurs du sein triple-négatives / Récepteur-1 à domaine discoïdine Type d'étude: Prognostic_studies Limites: Animals / Female / Humans Langue: En Journal: Nature Année: 2021 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Royaume-Uni